{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:39:14Z","timestamp":1778200754129,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K16136"],"award-info":[{"award-number":["20K16136"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08430"],"award-info":[{"award-number":["23K08430"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15143"],"award-info":[{"award-number":["23K15143"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jphs.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T11:42:51Z","timestamp":1683891771000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of electropharmacological profile of an anti-atrial fibrillatory drug vernakalant along with potential risk toward torsade de pointes: Translational studies using isoflurane-anesthetized dogs and isolated rat aortic preparations"],"prefix":"10.1016","volume":"152","author":[{"given":"Ai","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2023.05.003_bib1","series-title":"Basic & clinical pharmacology","first-page":"235","article-title":"Agents used in cardiac arrhythmias","author":"Harver","year":"2021"},{"key":"10.1016\/j.jphs.2023.05.003_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1573403X10666140513103709","article-title":"The vernakalant story: How did it come to approval in Europe and what is the delay in the U.S.A?","volume":"10","author":"Camm","year":"2014","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jphs.2023.05.003_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/europace\/eut274","article-title":"Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines","volume":"16","author":"Savelieva","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.jphs.2023.05.003_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/j.1540-8167.2005.50028.x","article-title":"The mechanism of atrial antiarrhythmic action of RSD1235","volume":"16","author":"Fedida","year":"2005","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jphs.2023.05.003_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","article-title":"A\u00a0randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation","volume":"57","author":"Camm","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jphs.2023.05.003_bib7","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","article-title":"Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial","volume":"117","author":"Roy","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jphs.2023.05.003_bib8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","article-title":"Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial","volume":"2","author":"Kowey","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jphs.2023.05.003_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/europace\/eur416","article-title":"Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.jphs.2023.05.003_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2013.10.054","article-title":"Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model","volume":"720","author":"Varkevisser","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2023.05.003_bib11","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2004.09.021","article-title":"A\u00a0randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation","volume":"44","author":"Roy","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jphs.2023.05.003_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jphs.2020.10.001","article-title":"In\u00a0vivo comparison of dl-sotalol-induced electrocardiographic responses among halothane anesthesia, isoflurane anesthesia with nitrous oxide, and conscious state","volume":"145","author":"Saito","year":"2020","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2023.05.003_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jphs.2020.12.010","article-title":"In\u00a0vivo analysis of concentration-dependent effects of halothane or isoflurane inhalation on the electrocardiographic and hemodynamic variables in dogs","volume":"145","author":"Saito","year":"2021","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2023.05.003_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12012-017-9434-y","article-title":"In\u00a0vivo analysis of the anti- atrial fibrillatory, proarrhythmic and cardiodepressive profile of dronedarone as a guide for safety pharmacological evaluation of antiarrhythmic drugs","volume":"18","author":"Motokawa","year":"2018","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jphs.2023.05.003_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12012-016-9369-8","article-title":"Anti-atrial fibrillatory versus proarrhythmic potentials of amiodarone: a new protocol for safety evaluation in\u00a0vivo","volume":"17","author":"Matsukura","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jphs.2023.05.003_bib16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1253\/circj.72.1003","article-title":"Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs","volume":"72","author":"Ishizaka","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.jphs.2023.05.003_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00380-021-01830-1","article-title":"In\u00a0vivo characterization of anti-atrial fibrillatory potential and pharmacological safety profile of INa,L plus IKr inhibitor ranolazine using the halothane-anesthetized dogs","volume":"36","author":"Nunoi","year":"2021","journal-title":"Heart Ves"},{"key":"10.1016\/j.jphs.2023.05.003_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jphs.2023.05.003_bib19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/bjp.2008.240","article-title":"Sensitive and reliable proarrhythmia in\u00a0vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts","volume":"154","author":"Sugiyama","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2023.05.003_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1254\/jjp.88.414","article-title":"Effects of a typical IKr channel blocker sematilide on the relationship between ventricular repo- larization, refractoriness and onset of torsades de pointes","volume":"88","author":"Sugiyama","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.jphs.2023.05.003_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the elec- trocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J\u00a0Pharmacol Methods"},{"key":"10.1016\/j.jphs.2023.05.003_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12576-021-00801-5","article-title":"Effects of mechanical ventilation with expiratory negative airway pressure on porcine pulmonary and systemic circulation: mechano-physiology and potential application","volume":"71","author":"Hagiwara-Nagasawa","year":"2021","journal-title":"J\u00a0Physiol Sci"},{"key":"10.1016\/j.jphs.2023.05.003_bib23","first-page":"215","article-title":"Pharmacotherapy options in atrial fibrillation: focus on vernakalant","volume":"1","author":"Cheng","year":"2009","journal-title":"Clin Med Insights Ther"},{"key":"10.1016\/j.jphs.2023.05.003_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbiomolbio.2020.08.004","article-title":"Autonomic modulation of sinoatrial node: role of pacemaker current and calcium sensitive adenylyl cyclase isoforms","volume":"166","author":"Robinson","year":"2021","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.jphs.2023.05.003_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FJC.0b013e318210276b","article-title":"Comparison of the in\u00a0vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model","volume":"57","author":"Allison","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861323000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:03:00Z","timestamp":1761163380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861323000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1347861323000336"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2023.05.003","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of electropharmacological profile of an anti-atrial fibrillatory drug vernakalant along with potential risk toward torsade de pointes: Translational studies using isoflurane-anesthetized dogs and isolated rat aortic preparations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}